Keywords: gsk/vertex, lexiva, effective, suppressing, hiv, over, years
GSK/Vertex' Lexiva effective in suppressing HIV over two years in therapy-naive patients
Article | 19 July 2004
New data presented at the XV International AIDS Conference in Bangkok,Thailand, suggest that GlaxoSmithKline/Vertex' protease inhibitor, Lexiva/Telzir ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
